9.78 USD
▼-0.51-4.96%
盘后 9.92 +1.43%
2026-09-15
市值
$851.35M
市盈率
—
EPS
-2.13
股息率
—
52 周区间
6.65 – 36.26
成交量
1.73M
Beta
1.99
目标价
39.30
52W 低 6.6552W 高 36.26
价格走势
公司简介
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. The company’s lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in seco...